Adherence to antipsychotics and cardiometabolic medication: Association with health care utilization and costs

Psychiatric Services

Volumn 63, Issue 9, 2012, Pages 920-928

  Hansen, Richard A ^a   Maciejewski, Matthew ^b,c   Yu Isenberg, Kristina ^d   Farley, Joel F ^e  

^a AUBURN UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

^e University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOMETABOLIC MEDICATION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NEUROLEPTIC AGENT; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTPATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; SCHIZOPHRENIA; TIME SERIES ANALYSIS;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HEALTH SERVICES; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LOGISTIC MODELS; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84866493833     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201100328     Document Type: Article

References (43)

1. Wu EQ, Shi L, Birnbaum H, et al: Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychological Medicine 36:1535-1540, 2006 (Pubitemid 44575799)
2. Wu EQ, Birnbaum HG, Shi L, et al: The economic burden of schizophrenia in the United States in 2002. Journal of Clinical Psychiatry 66:1122-1129, 2005 (Pubitemid 41442278)
3. Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 161:1-56, 2004
4. McCombs JS, Nichol MB, Stimmel GL, et al: Use patterns for antipsychotic medications in Medicaid patients with schizophrenia. Journal of Clinical Psychiatry 60(suppl 19):5-11, 1999 (Pubitemid 29446944)
5. Valenstein M, Copeland LA, Blow FC, et al: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 40:630-639, 2002
6. Lacro JP, Dunn LB, Dolder CR, et al: Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 63:892-909, 2002 (Pubitemid 35231730)
7. Gilmer TP, Dolder CR, Lacro JP, et al: Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161:692-699, 2004 (Pubitemid 38445514)
8. Dolder CR, Lacro JP, Dunn LB, et al: Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry 159:103-108, 2002 (Pubitemid 41070734)
9. Dolder CR, Lacro JP, Jeste DV: Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosomatic Medicine 65:156-162, 2003 (Pubitemid 36143209)
10. Sun SX, Liu GG, Christensen DB, et al: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Current Medical Research and Opinion 23:2305-2312, 2007 (Pubitemid 350033432)
11. Haywood TW, Kravitz HM, Grossman LS, et al: Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. American Journal of Psychiatry 152:856-861, 1995
12. Sullivan G, Wells KB, Morgenstern H, et al: Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. American Journal of Psychiatry 152:1749-1756, 1995
13. Piette JD, Heisler M, Ganoczy D, et al: Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension. Psychiatric Services 58:207-212, 2007 (Pubitemid 46340464)
14. Jeste SD, Patterson TL, Palmer BW, et al: Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophrenia Research 63:49-58, 2003 (Pubitemid 36929845)
15. Folsom DP, McCahill M, Bartels SJ, et al: Medical comorbidity and receipt of medical care by older homeless people with schizophrenia or depression. Psychiatric Services 53:1456-1460, 2002 (Pubitemid 35247256)
16. Druss BG, Bradford WD, Rosenheck RA, et al: Quality of medical care and excess mortality in older patients with mental disorders. Archives of General Psychiatry 58:565-572, 2001 (Pubitemid 32523736)
17. Weiss AP, Henderson DC, Weilburg JB, et al: Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatric Services 57:1145-1152, 2006 (Pubitemid 44204908)
18. Dolder CR, Furtek K, Lacro JP, et al: Antihypertensive medication adherence and blood pressure control in patients with psychotic disorders compared to persons without psychiatric illness. Psychosomatics 46:135-141, 2005 (Pubitemid 41071499)
19. Correll CU, Druss BG, Lombardo I, et al: Findings of a US national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatric Services 61:892-898, 2010
20. Nasrallah HA, Meyer JM, Goff DC, et al: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86:15-22, 2006 (Pubitemid 44234064)
21. Hennekens CH, Hennekens AR, Hollar D, et al: Schizophrenia and increased risks of cardiovascular disease. American Heart Journal 150:1115-1121, 2005 (Pubitemid 41773510)
22. Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 177:212-217, 2000
23. Goff DC, Cather C, Evins AE, et al: Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. Journal of Clinical Psychiatry 66:183-194, 2005
24. Stahl SM, Mignon L, Meyer JM: Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatrica Scandinavica 119:171-179, 2009
25. Sokol MC, McGuigan KA, Verbrugge RR, et al: Impact of medication adherence on hospitalization risk and health care cost. Medical Care 43:521-530, 2005 (Pubitemid 40847288)
26. Nelson LA, Graham MR, Lindsey CC, et al: Adherence to antihyperlipidemic medication and lipid control in diabetic Veterans Affairs patients with psychotic disorders. Psychosomatics 52:310-318, 2011
27. Knapp M, King D, Pugner K, et al: Nonadherence to antipsychotic medication regimens: associations with resource use and costs. British Journal of Psychiatry 184:509-516, 2004 (Pubitemid 38725711)
28. Ascher-Svanum H, Faries DE, Zhu B, et al: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry 67:453-460, 2006
29. Ward A, Ishak K, Proskorovsky I, et al: Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clinical Therapeutics 28:1912-1921, 2006 (Pubitemid 46038522)
30. Beebe LH, Smith K, Crye C, et al: Telenursing intervention increases psychiatric medication adherence in schizophrenia outpatients. Journal of the American Psychiatric Nurses Association 14:217-224, 2008
31. Weiden P, Aquila R, Standard J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical sychiatry 57(suppl 11):53-60, 1996
32. Nicholl D, Akhras KS, Diels J, et al: Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Current Medical Research and Opinion 26:943-955, 2010
33. Lurie N, Popkin M, Dysken M, et al: Accuracy of diagnoses of schizophrenia in Medicaid claims. Hospital and Community Psychiatry 43:69-71, 1992
34. Briesacher BA, Andrade SE, Fouayzi H, et al: Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437-443, 2008 (Pubitemid 351466455)
35. Karve S, Cleves MA, Helm M, et al: Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value in Health 12:989-995, 2009
36. Benner JS, Glynn RJ, Mogun H, et al: Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455-461, 2002 (Pubitemid 34787476)
37. Karve S, Cleves MA, Helm M, et al: Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Current Medical Research and Opinion 25:2303-2310, 2009
38. Quan H, Sundararajan V, Halfon P, et al: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 43:1130-1139, 2005 (Pubitemid 41587600)
39. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Journal of Clinical Psychiatry 65:267-272, 2004
40. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005 (Pubitemid 41345943)
41. Starrenburg FC, Bogers JP: How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. European Psychiatry 24:164-170, 2009
42. Zygmunt A, Olfson M, Boyer CA, et al: Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 159:1653-1664, 2002
43. Hansen RA, Dusetzina SB, Dominik RC, et al: Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiology and Drug Safety 19:33-37, 2010